Myelin peptides in multiple sclerosis

L. Grau-López, D. Raïch, C. Ramo-Tello, M. Naranjo-Gómez, A. Dàvalos, R. Pujol-Borrell, F. E. Borràs, E. Martínez-Cáceres

Research output: Contribution to journalReview articleResearchpeer-review

25 Citations (Scopus)


The development of specific therapies for organ-specific autoimmune diseases requires the identification of relevant immunogenic epitopes, recognized by both pathogenic T cells and autoantibodies. Here, we review the most relevant studies focused in the identification of peptides in multiple sclerosis (MS) and the distinct T cell reactivity induced in patients compared to controls. Only a few studies reported significant differences in terms of T cell reactivity to them. The current knowledge on this issue, and the diagnostic and therapeutic possibilities opened by the identification of pathogenic MS epitopes are discussed in this paper. © 2009 Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)650-653
JournalAutoimmunity Reviews
Issue number8
Publication statusPublished - 1 Jul 2009


  • Cell proliferation
  • Cell therapy
  • Multiple sclerosis
  • Myelin peptides
  • T-cell reactivity


Dive into the research topics of 'Myelin peptides in multiple sclerosis'. Together they form a unique fingerprint.

Cite this